
    
      This is a open-label (all people know the identity of the intervention), single arm,
      multicenter study. The study will consist of a screening phase up to 4 weeks, open-label
      treatment phase of 12 weeks, and post-treatment follow up phase up to 24 weeks after end of
      treatment. Approximately 100 participants will receive 150 mg simeprevir in combination with
      400 mg sofosbuvir once dailyfor 12 weeks. Safety evaluations will include assessment of
      adverse events, clinical laboratory tests, vital signs, and physical examination. The maximum
      study duration for each participant will be approximately 40 weeks.
    
  